Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win
Praxis Precision Medicines, Inc. ripped higher again on 5 December 2025, extending one of the most dramatic biotech rallies of the year after positive epilepsy data and a favorable pre‑NDA meeting with the FDA. By the closing bell on Friday, PRAX finished at $247.99, up 30.5% on the day, with a new 52‑week range of $26.70–$277.44 and a market capitalization around $6.2 billion. StockAnalysis+1